Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 3;11:536442. doi: 10.3389/fimmu.2020.536442

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Smith, Culver-Cochran, Adelman, Rhyasen, Ma, Figueroa and Starczynowski

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Heterozygous deletion of A20 results in a competitive advantage of hematopoietic stem and progenitor cells. (A) Outline of competitive BM transplantations using VavCre⁺ or A20^+/-VavCre⁺ mice. (B) Summary of donor-derived PB proportions at the indicated time points after competitive transplantation using VavCre⁺ or A20^+/-VavCre⁺ BM cells (n = 10 per group). (C) Proportion of donor-derived VavCre⁺ or A20^+/-VavCre⁺ myeloid (CD11b⁺) and lymphoid (CD3⁺ and B220⁺) proportions at 16 weeks following competitive transplantation (n = 9 per group). (D-F) Summary of donor-derived BM HSPC proportions at 16 weeks after competitive transplantation using VavCre⁺ or A20^+/-VavCre⁺ BM cells (n = 9 per group). *P < 0.05. Data are represented as mean ± SEM.